CD4 and HIV-1 infection: Thus, we evaluated the antiviral activity of selective JAK2i fedratinib and AZD1480, and the pan-JAKi ruxolitinib, in acute HIV-1 infection in primary CD4+T cells from healthy donors (n=3).